ATL-105
Non-Cystic Fibrosis Bronchiectasis (NCFB)
Pre-clinicalActive
Key Facts
Indication
Non-Cystic Fibrosis Bronchiectasis (NCFB)
Phase
Pre-clinical
Status
Active
Company
About AATec Medical
AATec Medical, founded in 2016 and based in Munich, is a preclinical-stage biotech targeting major unmet needs in inflammatory respiratory diseases. Its core asset is a proprietary recombinant Alpha-1 Antitrypsin (AAT) platform, designed with multimodal anti-protease, immunomodulatory, and anti-infective properties for direct lung delivery. The lead candidate, ATL-105, is being developed for non-cystic fibrosis bronchiectasis (NCFB), with clinical studies planned for 2026, and has potential expansion into large markets like COPD and asthma.
View full company profile